US · NKTX
Nkarta, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- South San Francisco, CA 94080
- Website
- nkartatx.com
Price · as of 2024-12-31
$2.93
Market cap 191.78M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $0.00 | $201.30 | |||
| 2020 | $48.78 | $39.32 | |||
| 2021 | $9.96 | ||||
| 2022 | $3.78 | ||||
| 2023 | $14.63 | ||||
| 2024 | $1.84 |
AI valuation
Our deep-learning model estimates Nkarta, Inc.'s (NKTX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $2.93
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NKTX | Nkarta, Inc. | $2.93 | 191.78M | — | — | — | — | -1.15 | 0.31 | — | 0.52 | — | 0.31 | 0.00% | — | — | -31.94% | -76.69% | -24.72% | 0.20 | — | 14.45 | 14.14 | -0.44 | -3333.00% | — | -893.00% | -83.37% | -5.27 | -62.28% | 0.00% | 0.00% | 3.92% | 0.49 | 0.60 | — | -0.95 |
| ALEC | Alector, Inc. | $2.43 | 265.24M | +1,084% | -64% | — | +3,751% | -1.59 | 7.43 | 10.82 | -0.06 | -12.24 | 7.43 | 54.09% | -692.83% | -679.16% | -181.56% | 67.31% | -37.54% | 1.18 | — | 3.83 | 3.68 | 0.22 | 1301.00% | -7907.00% | -2037.00% | -80.87% | -2.65 | 84.98% | 0.00% | 0.00% | 17.16% | -0.05 | -0.04 | 0.37 | -4.88 |
| APLT | Applied Therapeutics, Inc… | $0.10 | 14.86M | +30,191% | +123% | — | +60,988% | -0.76 | 1.40 | 175.54 | -0.03 | — | 1.40 | 100.00% | -22922.86% | -23214.07% | -529.97% | 242.94% | -149.27% | 0.05 | — | 3.06 | 2.91 | 0.74 | -4648.00% | -9545.00% | 5280.00% | -105.55% | -3.09 | 196.37% | 0.00% | 0.00% | 34.41% | -0.03 | -0.04 | 7.18 | -10.84 |
| ELTX | Elicio Therapeutics, Inc. | $12.99 | 224.19M | — | — | — | — | -1.86 | -8.51 | — | -2.08 | — | -8.51 | 0.00% | — | — | -170157.38% | -3590.26% | -187.61% | -2.30 | -98.87 | 1.80 | 1.53 | -0.17 | -3894.00% | — | 1342.00% | -38.59% | -3.22 | -2965.28% | 0.00% | 0.00% | 0.00% | -2.33 | -2.82 | — | -13.06 |
| FATE | Fate Therapeutics, Inc. | $1.48 | 170.72M | +1,664% | -45% | — | +3,067% | -1.31 | 0.86 | 26.81 | -0.41 | — | 0.86 | -94.12% | -2222.45% | -2051.08% | -51.84% | -143.19% | -35.89% | 0.38 | — | 5.79 | 5.67 | -0.25 | -2988.00% | -5124.00% | -936.00% | -62.88% | -2.94 | -108.62% | 0.00% | 0.00% | 10.10% | -0.35 | -0.47 | 7.88 | -6.64 |
| FBRX | Forte Biosciences, Inc. | $30.22 | 378.56M | — | — | — | — | -0.53 | 0.36 | — | 1.11 | — | 0.36 | 0.00% | — | — | -80.82% | 951.20% | -70.57% | 0.00 | — | 6.76 | 6.43 | 0.63 | -5116.00% | — | 690.00% | -162.41% | -3.39 | 799.95% | 0.00% | 0.00% | 54.26% | 1.08 | 1.28 | — | -3.19 |
| MOLN | Molecular Partners AG | $5.02 | 187.84M | +527% | -29% | — | +690% | -2.52 | 0.96 | 27.41 | 0.21 | — | 0.96 | -855.81% | -1231.73% | -1087.38% | -33.98% | 1006.36% | -30.29% | 0.02 | -2448.68 | 14.31 | 13.88 | 1.19 | -1587.00% | -2938.00% | 26.00% | -44.02% | -5.49 | 985.88% | 0.00% | 0.00% | 0.00% | 0.18 | 0.18 | -2.17 | 2.51 |
| PEPG | PepGen Inc. | $6.22 | 427.61M | — | — | — | — | -0.81 | 0.61 | — | 0.32 | — | 0.61 | 0.00% | — | — | -79.26% | -551.43% | -61.23% | 0.16 | — | 7.41 | 7.20 | 0.35 | -1364.00% | — | 1575.00% | -113.83% | -4.93 | -470.74% | 0.00% | 0.00% | 0.00% | 0.29 | 0.35 | — | -2.45 |
| SAVA | Cassava Sciences, Inc. | $2.28 | 110.14M | — | — | — | — | -5.35 | 0.89 | — | -0.01 | — | 0.89 | 0.00% | — | — | -17.19% | -845.41% | -15.75% | 0.00 | — | 11.62 | 11.02 | 0.91 | -7759.00% | — | 4196.00% | -89.90% | -9.95 | -699.49% | 0.00% | 0.00% | 5.71% | -0.01 | -0.01 | — | 0.99 |
| VOR | Vor Biopharma Inc. | $15.44 | 105.82M | — | — | — | — | -0.59 | 0.71 | — | -0.07 | — | 0.71 | 0.00% | — | — | -94.52% | -282.56% | -66.29% | 0.33 | — | 5.19 | 4.94 | 0.43 | -286.00% | — | -145.00% | -145.39% | -5.35 | -232.90% | 0.00% | 0.00% | 79.21% | -0.07 | -0.09 | — | -5.73 |
About Nkarta, Inc.
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
- CEO
- Paul J. Hastings
- Employees
- 157
- Beta
- 0.52
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $2.93) − 1 = — (DCF, example).